PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

IPOS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number:
C07K 16/28, A61K 39/395	A1	**WO 98/37099**
		(43) International Publication Date: 27 August 1998 (27.08.98)

(21) International Application Number: PCT/US98/02253

(22) International Filing Date: 17 February 1998 (17.02.98)

(30) Priority Data:

08/803,085	20 February 1997 (20.02.97)	US
Not furnished	5 February 1998 (05.02.98)	US

(71) Applicants: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road, San Diego, CA 92121 (US). SEIKAGAKU CORPORATION [JP/JP]; Tokyo Yakugyo Building, 2–1–5, Nihonbashi–honcho, Chuo–ku, Tokyo 103 (JP).

(72) Inventors: REFF, Mitchell, E.; 4166 Combe Way, San Diego, CA 92122 (US). KLOETZER, William, S.; 4317 Sea Bright Drive, Carlsbad, CA 92008 (US). NAKAMURA, Takehiko; Tokyo Research Institute, 1253, Tateno 3–chome, Higashiyamato–shi, Tokyo 207 (JP).

(74) Agents: GESS, E., Joseph et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313–1404 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: GAMMA–1 AND GAMMA–3 ANTI–HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS

(57) Abstract

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma–1 or human gamma–3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.